1. T790M Mutation-Positive NSCLC: A Multidisciplinary Case Conference

3. Managing EGFR TKI Resistance

4. Patient Case: A Woman With EGFR Exon 19 Mutation-Positive Lung Cancer

5. Patient Case: Diagnostic Findings

6. Patient Case: Need for New Mutation Testing?

7. Lung Cancer Biomarkers Detected in Urine

8. Patient Case: Cytology Findings

9. First-Line EGFR TKIs in EGFR Mutation: Summary

10. LUX-Lung 7: PFS for Stratification by Exon 19 Deletion

11. Patient Case: First-Line Systemic Treatment

12. FASTACT-2: EGFR Sensitizing Mutations After 3 Months of Therapy

13. Patient Case Continued

14. Considerations for Assessment of T790M Mutations in Plasma

15. Suitability of an Allele Frequency Cutoff

16. Patient Case: Brain Imaging

17. TKIs in NSCLC With Brain Metastases

18. Potential for Mutation Testing in Brain Metastasis

19. Patient Case Continued

20. Plasma ctDNA Analysis for Detecting T790M in Advanced NSCLC

21. Plasma and Tumor Genotyping Concordance for T790M Mutations

22. Plasma and Tumor Genotyping Concordance for T790M Mutations: False-Positives?

23. Potential of Plasma Before Tissue Testing

24. EGFR Mutation Status in Matched Plasma and Tumor Tissue in a Study of Rociletinib*

25. DNA/RNA Sequencing Applications

26. Comparing Sensitivity of Testing Methods

27. Cost Factors in NGS

28. Patient Case Continued

29. Next-Generation EGFR TKIs in Development

30. Mechanisms of Resistance to Third-Generation EGFR TKIs

31. Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

32. Concluding Remarks

33. Abbreviations

34. Abbreviations